Search over 3,000 reports

    Cytomegalovirus (CMV) Infection- Epidemiology Forecast to 2023

    Cytomegalovirus (CMV) Infection- Epidemiology Forecast to 2023
    Date: Dec, 2017
    Type: Pharmaceutical Industry Report
    Pages: 40
    Geography: Global
    Delivery Timeline: 48 hrs
    SKU: DIEI0007
    Cytomegalovirus (CMV) infection is caused by Cytomegalovirus (CMV), a member of the herpes virus family. Upon initial infection, CMV infects the epithelial cells of the salivary gland, resulting in a persistent infection and viral shedding. Person can be infected with CMV at any point of time in life and is not easily diagnosed as no symptoms are shown.
    DelveInsight's "Cytomegalovirus (CMV) Infection- Epidemiology Insights-2023" Report provides an overview of the disease and the historical and forecasted epidemiological data for the Cytomegalovirus (CMV) Infection for Global, United States, EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan for the time period 2013-2023.
    The report considers the transplant patients, HIV patients and Infants under high risk for CMV infections and epidemiology forecast for these high risk categories have also been taken into consideration. Of The 7 Major Markets, U.S. has the highest number of CMV Prevalent cases and Spain has the least number of CMV Prevalent cases. According to DelveInsight, the Global Diagnosed cases for Cytomegalovirus (CMV) Infection are expected to increase at a CAGR of 0.047% during the period 2013-2023.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
    Scope
    Report covers the disease overview including etiology, pathophysiology, symptoms, diagnosis and disease management.

    Identifying patient populations in the global Cytomegalovirus (CMV) Infection market.

    The Report covers the detailed historical and forecasted epidemiological data covering global from 2013-2023.
    1. Cytomegalovirus Infections
    2. Disease Overview
    • Symptoms of cytomegalovirus (CMV) Infection
    • Etiology
    • Risk Factors
    • Pathogenesis of human cytomegalovirus
    • Pathophysiology of cytomegalovirus infection
    • Diagnosis
    3. Epidemiology and Patient Population
    • 7MM
    • 7MM CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2016)
    • 7MM CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2017-2023)
    4. United States
    • Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2016)
    • Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2017-2023)
    • CMV Patients among Transplants: Historical Data (2013-2016)
    • CMV Patients among Transplants: Forecasted Data (2017-2023)
    • Infants Patients at High Risk of CMV: Historical Data (2013-2016)
    • Infants Patients at High Risk of CMV: Forecasted Data (2017-2023)
    • HIV Patients at High Risk of CMV: Historical Data (2013-2016)
    • HIV Patients at High Risk of CMV: Forecasted Data (2017-2023)
    5. Europe
    5.1 Italy
    • Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2016)
    • Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2017-2023)
    • CMV Patients among Transplants: Historical Data (2013-2016)
    • CMV Patients among Transplants: Forecasted Data (2017-2023)
    • Infants Patients at High Risk of CMV: Historical Data (2013-2016)
    • Infants Patients at High Risk of CMV: Forecasted Data (2017-2023)
    • HIV Patients at High Risk of CMV: Historical Data (2013-2016)
    • HIV Patients at High Risk of CMV: Forecasted Data (2017-2023)
    5.2 Spain
    • Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2016)
    • Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2017-2023)
    • CMV Patients among Transplants: Historical Data (2013-2016)
    • CMV Patients among Transplants: Forecasted Data (2017-2023)
    • Infants Patients at High Risk of CMV: Historical Data (2013-2016)
    • Infants Patients at High Risk of CMV: Forecasted Data (2017-2023)
    • HIV Patients at High Risk of CMV: Historical Data (2013-2016)
    • HIV Patients at High Risk of CMV: Forecasted Data (2017-2023)
    5.3 United Kingdom
    • Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2016)
    • Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2017-2023)
    • CMV Patients among Transplants: Historical Data (2013-2016)
    • CMV Patients among Transplants: Forecasted Data (2017-2023)
    • Infants Patients at High Risk of CMV: Historical Data (2013-2016)
    • Infants Patients at High Risk of CMV: Forecasted Data (2017-2023)
    • HIV Patients at High Risk of CMV: Historical Data (2013-2016)
    • HIV Patients at High Risk of CMV: Forecasted Data (2017-2023)
    5.4 Germany
    • Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2016)
    • Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2017-2023)
    • CMV Patients among Transplants: Historical Data (2013-2016)
    • CMV Patients among Transplants: Forecasted Data (2017-2023)
    • Infants Patients at High Risk of CMV: Historical Data (2013-2016)
    • Infants Patients at High Risk of CMV: Forecasted Data (2017-2023)
    • HIV Patients at High Risk of CMV: Historical Data (2013-2016)
    • HIV Patients at High Risk of CMV: Forecasted Data (2017-2023)
    5.5 France
    • Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2016)
    • Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2017-2023)
    • CMV Patients among Transplants: Historical Data (2013-2016)
    • CMV Patients among Transplants: Forecasted Data (2017-2023)
    • Infants Patients at High Risk of CMV: Historical Data (2013-2016)
    • Infants Patients at High Risk of CMV: Forecasted Data (2017-2023)
    • HIV Patients at High Risk of CMV: Historical Data (2013-2016)
    • HIV Patients at High Risk of CMV: Forecasted Data (2017-2023)
    6. Japan
    • Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2016)
    • Total CMV Prevalent, Diagnosed and Treatable Cases: Forecasted Data (2017-2023)
    • CMV Patients among Transplants: Historical Data (2013-2016)
    • CMV Patients among Transplants: Forecasted Data (2017-2023)
    • Infants Patients at High Risk of CMV: Historical Data (2013-2016)
    • Infants Patients at High Risk of CMV: Forecasted Data (2017-2023)
    • HIV Patients at High Risk of CMV: Historical Data (2013-2016)
    • HIV Patients at High Risk of CMV: Forecasted Data (2017-2023)
    7. Unmet Medical Needs
    8. Assumptions and Rationale
    9. Appendix
    10. Report Methodology
    11. Consulting Services
    12. Disclaimer
    13. About DelveInsight
    Table 1: Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2016)
    Table 2: Total CMV Prevalent, Diagnosed and Treatable Cases: Foreacasted Data (2017-2023)
    Table 3: Total CMV Prevalent, Diagnosed and Treatable Cases for United States: Historical Data (2013-2016)
    Table 4: Total CMV Prevalent, Diagnosed and Treatable Cases for United States: Foreacasted Data (2017-2023)
    Table 5: CMV Patients among Transplants in United States: Historical Data (2013-2016)
    Table 6: CMV Patients among Transplants in United States: Foreacasted Data (2017-2023)
    Table 7: Infants Patients at High Risk of CMV in United States: Historical Data (2013-2016)
    Table 8: Infants Patients at High Risk of CMV in United States: Foreacasted Data (2017-2023)
    Table 9: HIV Patients at High Risk of CMV in United States: Historical Data (2013-2016)
    Table 10: HIV Patients at High Risk of CMV in United States: Foreacasted Data (2017-2023)
    Table 11: Total CMV Prevalent, Diagnosed and Treatable Cases for Italy: Historical Data (2013-2016)
    Table 12: Total CMV Prevalent, Diagnosed and Treatable Cases for Italy: Foreacasted Data (2017-2023)
    Table 13: CMV Patients among Transplants in Italy: Historical Data (2013-2016)
    Table 14: CMV Patients among Transplants in Italy: Foreacasted Data (2017-2023)
    Table 15: Infants Patients at High Risk of CMV in Italy: Historical Data (2013-2016)
    Table 16: Infants Patients at High Risk of CMV in Italy: Foreacasted Data (2017-2023)
    Table 17: HIV Patients at High Risk of CMV in Italy: Historical Data (2013-2016)
    Table 18: HIV Patients at High Risk of CMV in Italy: Foreacasted Data (2017-2023)
    Table 19: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain: Historical Data (2013-2016)
    Table 20: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain: Foreacasted Data (2017-2023)
    Table 21: CMV Patients among Transplants in Spain: Historical Data (2013-2016)
    Table 22: CMV Patients among Transplants in Spain: Foreacasted Data (2017-2023)
    Table 23: Infants Patients at High Risk of CMV in Spain: Historical Data (2013-2016)
    Table 24: Infants Patients at High Risk of CMV in Spain: Foreacasted Data (2017-2023)
    Table 25: HIV Patients at High Risk of CMV in Spain: Historical Data (2013-2016)
    Table 26: HIV Patients at High Risk of CMV in Spain: Foreacasted Data (2017-2023)
    Table 27: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom: Historical Data (2013-2016)
    Table 28: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom: Foreacasted Data (2017-2023)
    Table 29: CMV Patients among Transplants in United Kingdom: Historical Data (2013-2016)
    Table 30: CMV Patients among Transplants in United Kingdom: Foreacasted Data (2017-2023)
    Table 31: Infants Patients at High Risk of CMV in United Kingdom: Historical Data (2013-2016)
    Table 32: Infants Patients at High Risk of CMV in United Kingdom: Foreacasted Data (2017-2023)
    Table 33: HIV Patients at High Risk of CMV in United Kingdom: Historical Data (2013-2016)
    Table 34: HIV Patients at High Risk of CMV in United Kingdom: Foreacasted Data (2017-2023)
    Table 35: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany: Historical Data (2013-2016)
    Table 36: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany: Foreacasted Data (2017-2023)
    Table 37: CMV Patients among Transplants in Germany: Historical Data (2013-2016)
    Table 38: CMV Patients among Transplants in Germany: Foreacasted Data (2017-2023)
    Table 39: Infants Patients at High Risk of CMV in Germany: Historical Data (2013-2016)
    Table 40: Infants Patients at High Risk of CMV in Germany: Foreacasted Data (2017-2023)
    Table 41: HIV Patients at High Risk of CMV in Germany: Historical Data (2013-2016)
    Table 42: HIV Patients at High Risk of CMV in Germany: Foreacasted Data (2017-2023)
    Table 43: Total CMV Prevalent, Diagnosed and Treatable Cases for France: Historical Data (2013-2016)
    Table 44: Total CMV Prevalent, Diagnosed and Treatable Cases for France: Foreacasted Data (2017-2023)
    Table 45: CMV Patients among Transplants in France: Historical Data (2013-2016)
    Table 46: CMV Patients among Transplants in France: Foreacasted Data (2017-2023)
    Table 47: Infants Patients at High Risk of CMV in France: Historical Data (2013-2016)
    Table 48: Infants Patients at High Risk of CMV in France: Foreacasted Data (2017-2023)
    Table 49: HIV Patients at High Risk of CMV in France: Historical Data (2013-2016)
    Table 50: HIV Patients at High Risk of CMV in France: Foreacasted Data (2017-2023)
    Table 51: Total CMV Prevalent, Diagnosed and Treatable Cases for Japan: Historical Data (2013-2016)
    Table 52: Total CMV Prevalent, Diagnosed and Treatable Cases for Japan: Foreacasted Data (2017-2023)
    Table 53: CMV Patients among Transplants in Japan: Historical Data (2013-2016)
    Table 54: CMV Patients among Transplants in Japan: Foreacasted Data (2017-2023)
    Table 55: Infants Patients at High Risk of CMV in Japan: Historical Data (2013-2016)
    Table 56: Infants Patients at High Risk of CMV in Japan: Foreacasted Data (2017-2023)
    Table 57: HIV Patients at High Risk of CMV in Japan: Historical Data (2013-2016)
    Table 58: HIV Patients at High Risk of CMV in Japan: Foreacasted Data (2017-2023)
    Figure 1: Risk Factors CMV infection, 2017
    Figure 2: Total CMV Prevalent, Diagnosed and Treatable Cases: Historical Data (2013-2016)
    Figure 3: Total CMV Prevalent, Diagnosed and Treatable Cases: Foreacasted Data (2017-2023)
    Figure 4: Total CMV Prevalent, Diagnosed and Treatable Cases for United States: Historical Data (2013-2016)
    Figure 5: Total CMV Prevalent, Diagnosed and Treatable Cases for United States: Foreacasted Data (2017-2023)
    Figure 6: CMV Patients among Transplants in United States: Historical Data (2013-2016)
    Figure 7: CMV Patients among Transplants in United States: Foreacasted Data (2017-2023)
    Figure 8: Infants Patients at High Risk of CMV in United States: Historical Data (2013-2016)
    Figure 9: Infants Patients at High Risk of CMV in United States: Foreacasted Data (2017-2023)
    Figure 10: HIV Patients at High Risk of CMV in United States: Historical Data (2013-2016)
    Figure 11: HIV Patients at High Risk of CMV in United States: Foreacasted Data (2017-2023)
    Figure 12: Total CMV Prevalent, Diagnosed and Treatable Cases for Italy: Historical Data (2013-2016)
    Figure 13: Total CMV Prevalent, Diagnosed and Treatable Cases for Italy: Foreacasted Data (2017-2023)
    Figure 14: CMV Patients among Transplants in Italy: Historical Data (2013-2016)
    Figure 15: CMV Patients among Transplants in Italy: Foreacasted Data (2017-2023)
    Figure 16: Infants Patients at High Risk of CMV in Italy: Historical Data (2013-2016)
    Figure 17: Infants Patients at High Risk of CMV in Italy: Foreacasted Data (2017-2023)
    Figure 18: HIV Patients at High Risk of CMV in Italy: Historical Data (2013-2016)
    Figure 19: HIV Patients at High Risk of CMV in Italy: Foreacasted Data (2017-2023)
    Figure 20: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain: Historical Data (2013-2016)
    Figure 21: Total CMV Prevalent, Diagnosed and Treatable Cases for Spain: Foreacasted Data (2017-2023)
    Figure 22: CMV Patients among Transplants in Spain: Historical Data (2013-2016)
    Figure 23: CMV Patients among Transplants in Spain: Foreacasted Data (2017-2023)
    Figure 24: Infants Patients at High Risk of CMV in Spain: Historical Data (2013-2016)
    Figure 25: Infants Patients at High Risk of CMV in Spain: Foreacasted Data (2017-2023)
    Figure 26: HIV Patients at High Risk of CMV in Spain: Historical Data (2013-2016)
    Figure 27: HIV Patients at High Risk of CMV in Spain: Foreacasted Data (2017-2023)
    Figure 28: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom: Historical Data (2013-2016)
    Figure 29: Total CMV Prevalent, Diagnosed and Treatable Cases for United Kingdom: Foreacasted Data (2017-2023)
    Figure 30: CMV Patients among Transplants in United Kingdom: Historical Data (2013-2016)
    Figure 31: CMV Patients among Transplants in United Kingdom: Foreacasted Data (2017-2023)
    Figure 32: Infants Patients at High Risk of CMV in United Kingdom: Historical Data (2013-2016)
    Figure 33: Infants Patients at High Risk of CMV in United Kingdom: Foreacasted Data (2017-2023)
    Figure 34: HIV Patients at High Risk of CMV in United Kingdom: Historical Data (2013-2016)
    Figure 35: HIV Patients at High Risk of CMV in United Kingdom: Foreacasted Data (2017-2023)
    Figure 36: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany: Historical Data (2013-2016)
    Figure 37: Total CMV Prevalent, Diagnosed and Treatable Cases for Germany: Foreacasted Data (2017-2023)
    Figure 38: CMV Patients among Transplants in Germany: Historical Data (2013-2016)
    Figure 39: CMV Patients among Transplants in Germany: Foreacasted Data (2017-2023)
    Figure 40: Infants Patients at High Risk of CMV in Germany: Historical Data (2013-2016)
    Figure 41: Infants Patients at High Risk of CMV in Germany: Foreacasted Data (2017-2023)
    Figure 42: HIV Patients at High Risk of CMV in Germany: Historical Data (2013-2016)
    Figure 43: HIV Patients at High Risk of CMV in Germany: Foreacasted Data (2017-2023)
    Figure 44: Total CMV Prevalent, Diagnosed and Treatable Cases for France: Historical Data (2013-2016)
    Figure 45: Total CMV Prevalent, Diagnosed and Treatable Cases for France: Foreacasted Data (2017-2023)
    Figure 46: CMV Patients among Transplants in France: Historical Data (2013-2016)
    Figure 47: CMV Patients among Transplants in France: Foreacasted Data (2017-2023)
    Figure 48: Infants Patients at High Risk of CMV in France: Historical Data (2013-2016)
    Figure 49: Infants Patients at High Risk of CMV in France: Foreacasted Data (2017-2023)
    Figure 50: HIV Patients at High Risk of CMV in France: Historical Data (2013-2016)
    Figure 51: HIV Patients at High Risk of CMV in France: Foreacasted Data (2017-2023)
    Figure 52: Total CMV Prevalent, Diagnosed and Treatable Cases for Japan: Historical Data (2013-2016)
    Figure 53: Total CMV Prevalent, Diagnosed and Treatable Cases for Japan: Foreacasted Data (2017-2023)
    Figure 54: CMV Patients among Transplants in Japan: Historical Data (2013-2016)
    Figure 55: CMV Patients among Transplants in Japan: Foreacasted Data (2017-2023)
    Figure 56: Infants Patients at High Risk of CMV in Japan: Historical Data (2013-2016)
    Figure 57: Infants Patients at High Risk of CMV in Japan: Foreacasted Data (2017-2023)
    Figure 58: HIV Patients at High Risk of CMV in Japan: Historical Data (2013-2016)
    Figure 59: HIV Patients at High Risk of CMV in Japan: Foreacasted Data (2017-2023)


    Cytomegalovirus (CMV) Infection Disease Overview

    Cytomegalovirus (CMV) Infection Prevalence

    Cytomegalovirus (CMV) Infection Incidence

    Cytomegalovirus (CMV) Infection Risk Factors

    Cytomegalovirus (CMV) Infection Epidemiology

    Cytomegalovirus (CMV) Infection Patient Populations

    Cytomegalovirus (CMV) Infection Diagnosed Patients

    Cytomegalovirus (CMV) Infection Forecast

    Cytomegalovirus (CMV) Infection Epidemiology Forecast

    Cytomegalovirus (CMV) Infection Treated patients/population

    • Single User License
      (20% Off)
      $2,750.00
    • Site License
      (30% Off)
      $5,500.00
    • Global License
      (40% Off)
      $8,250.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap